Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma

Prognoses for patients with metastatic urothelial carcinoma (mUC) have improved with pembrolizumab treatment, an immune checkpoint inhibitor, but clinical benefits are limited to a subset of patients. Therefore, a non-invasive biomarker to predict pembrolizumab response is required. The present stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Kazuki, Nagumo, Yoshiyuki, Kandori, Shuya, Tanuma, Kozaburo, Shiga, Masanobu, Hoshi, Akio, Negoro, Hiromitsu, Kojima, Takahiro, Mathis, Bryan J., Nishiyama, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407860/
https://www.ncbi.nlm.nih.gov/pubmed/37559592
http://dx.doi.org/10.3892/ol.2023.13975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407860/
https://www.ncbi.nlm.nih.gov/pubmed/37559592
http://dx.doi.org/10.3892/ol.2023.13975

Ejemplares similares